Roche says EU panel backs lymphatic cancer drug for approval

ZURICH Fri Jan 24, 2014 12:03pm EST

Related Topics

ZURICH (Reuters) - Swiss drug company Roche said on Friday a European Union committee recommended its MabThera subcutaneous treatment for patients with non-Hodgkin lymphoma.

Roche said the opinion of the EU Committee for Medicinal Products for Human Use (CHMP) was based primarily on data from a phase III study, with a final decision from the European Commission expected in coming months.

The Commission generally follows committee recommendations, though it is not obliged to.

MabThera is a treatment for non-Hodgkin lymphoma, a cancer of the lymphatic system, and is currently delivered by an intravenous infusion which takes 2-1/2 hours to complete.

In contrast, the new MabThera subcutaneous formulation can be delivered over approximately five minutes, Roche said.

(Reporting by Alice Baghdjian)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
Mylena wrote:
Good for Roche. There are outside thousands of Phamaceutical that in the last 30 years they did not a f…. thing to fight cancer. GOOD FOR YOU ROCHE!!!!!

Jan 24, 2014 12:53pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.